PubMed Health⌕ Search

Biomedical subjects

G V Kruglova

Publications and source records attributed to G V Kruglova.

At least 19 recordsLinked to original sources
PubMed2001

[Effectiveness of treatment of recurrences of non-Hodgkin's lymphoma after combined chemoradiotherapy depending on prognostic indicators].

The results were evaluated of the management of non-Hodgkin's lymphomas in 46 out of 150 patients relapsing after first complete remission, following early-stage chemoradiotherapy. Polychemotherapy of recurrent tumors was given to 85% (39/46), repeat combined treatment--13% (6/46) and radiotherapy--2% (1/46). Remission was reported in 91% (42/46): complete--69% (32) and partial--22% (10). Remission frequency and duration directly depended on degree of risk (IPI), stage of recurrence development and advancement, tumor size and general symptoms of intoxication. There was no relationship between frequency and duration, on the one hand, and sex and age, tumor pattern or number of involvement areas, on the other. Instead, the efficacy was influenced by the general condition of the patient, damage to the lymph nodes rather than adjacent areas as well as number of such areas. LDH blood level impacted the end results.

Adolescent↗
PubMed1999

[Richter's syndrome: analysis of literature data and original observations].

AIM: Review of literature data and original experience with Richter's syndrome. MATERIALS AND METHODS: 250 patients suffering from malignant lymphoproliferative diseases with blood and bone marrow lymphocytosis were observed. 8 (3.2%) of them developed diffuse large-cell lymphoma (criteria and classification of REAL). RESULTS: 5 of the above 8 patients demonstrated spontaneous regression of lymphocytosis. These cases may illustrate transformation (clonal progression) of one morphological variant of malignant non-Hodgkin's lymphoma into another one, more aggressive. For this rare variant of Richter's syndrome running with regression of lymphocytosis the term Richter-Lortolary syndrome is proposed. Lortolary was the first who revealed a decrease of lymphocytosis in Richter's syndrome. The studies of the genome structure, first of all, of immunoglobulin genes show that in Richter-Lortolary syndrome it is easier, to confirm monoclonality of the two tumors (lymphocytic and large-cell) than to reject it. However, the idea of transformation has not been confirmed morphologically yet. CONCLUSION: Development of diffuse large-cell lymphoma in the course of chronic lymphatic tumor does not always indicate terminal state, later stage of tumor progression and poor prognosis.

Female↗
PubMed1996

[The prolymphocytic-lymphocytic leukemization of B-cell lymphosarcomas].

The paper presents clinical, hematological, morphological and immunological characteristics of B-cell lymphosarcoma with prolymphocytic-lymphocytic type of leukemization in 50 adult patients (9 females and 41 males aged 29-86 years). In B-cell immunological subvariant of prolymphocytic-lymphocytic leukemization changes in the primary tumor always corresponded to prolymphocytic variant of lymphosarcoma. This distinguishes B-cell lymphosarcomas from previously described T-cellular ones in which the type of eventual leukemic changes did not always correspond to the kind of initial tumor. The presence or absence of prolymphocytes with split nuclei in bone marrow puncture samples was neither of clinical nor of prognostic significance. In leukemization of B-cell prolymphocytic lymphosarcoma from the cells with split nuclei or cells with different configuration of the nuclei, immunological phenotype typical for B-cell chronic lymphoid leukemia did not occur. In prolymphocytic lymphosarcoma from cells with round nuclei one-third of patients had immunological phenotype more typical for B-cell chronic lymphoid leukemia. However, among them were patients with aggressive course with predominant extranodal location of tumor and prolymphocytic type of leukemization. Tumor nodes in B-cell prolymphocytic lymphosarcomas, irrespective of leukemization morphological variant, proved rather resistant to therapy. A complete clinicohematological remission according to the international criteria occurred in 2 of 50 patients, only.

Adult↗
PubMed1995

[The prolymphocytic-lymphocytic leukemization of T-cell lymphosarcomas].

The paper presents a detailed clinical, hematological, morphological, ultrastructural and immunological characterisation of T-cell lymphosarcoma with prolymphocytic-lymphocytic leukemic transformation (PLLT). In PLLT the proportion of T-cell immunological subvariant of lymphosarcoma came to 15% being detected only in 8 out of 52 examinees. The patients (6 males and 2 females) varied in age from 24 to 76 years (median 49 years) and had the following histological forms of primary tumor tissue: lymphoblastic lymphosarcoma (n = 3), pleiomorphic small cell lymphosarcoma (n = 1), large-cell anaplastic lymphosarcoma (n = 1), prolymphocytic lymphosarcoma. Immunological characteristics of these 8 cases were heterogeneous: in lymphoblastic variant there was immature T-immunological phenotype. In pleomorphic small-cell lymphosarcoma there were also signs of T-cell activation. In large-cell anaplastic lymphosarcoma an immunological phenotype of lymphoid cells from the primary tumor tissue and bone marrow differed in more advanced immunological differentiation of bone marrow tumor cells. In prolymphocytic variant tumor cells had features of T-helpers or T-suppressors. Most of the patients received polychemotherapy according to the schemes for high-grade lymphosarcomas despite PLLT though the latter is not a universal indicator of late tumor progression, more aggressive course of the disease and poor prognosis.

Adult↗
PubMed1994

[The clinicoimmunological characteristics of blast transformation in lymphosarcomas].

The authors studied a blast cell immunological phenotype in 50 adults with lymphosarcoma undergoing leukemization following the pattern of acute leukemia. Among the patients there were 12 females and 38 males aged 14-61. Immunological phenotyping of tumor cells was performed using a panel of monoclonal antibodies to T- and B-lymphocyte antigens, to myelomonocytic cells, some nonlinear and activation antigens. T, B and zero variants of blast cells were identified. Occasionally, blast cells carried nonlymphoid antigens and those corresponding to the common lymphosarcoma subvariant. Leukemization in the direction of lymphoblastic leukemia is associated with greater frequency of lymphosarcoma T subvariant (46%). B-cell and zero subvariants occurred in 28% and 20% of the patients, respectively. The number of complete remissions in the group of patients with T-cell subvariant was greater than in the group with B-cell subvariant. The survival in these two groups, however, was almost similar (median up to 8-12 months). Further studies into lymphoblastic leukemization immunophenotyping can help design programs of differentiated polychemotherapy.

Adolescent↗
PubMed1991

[The results of the combined chemoradiation treatment of lymphosarcomas corresponding to the degree of its intensity].

The authors describe the results of combined chemoradiotherapy of different intensity in 117 patients. It has been discovered that the differences in the results obtained were dependent on the stage of the treatment at which there ensured remissions rather than on the treatment intensity. The more rapidly complete remissions were attained the better were the long-term results, for the treatment continued during remissions turned out consolidating.

Adolescent↗
PubMed1990

Immuno-isotachophoretic determination of monoclonal immunoglobulin light chains produced by neoplastic B-cells: use in diagnosis, monitoring and detection of residual disease.

We suggest that countercurrent isotachophoresis performed on cellulose acetate membranes (ITP-CAM) should be used for detecting trace amounts of Bence-Jones protein (BJP) in urine of patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) and related diseases. ITP-CAM allows simultaneous concentration and electrophoretic separation of proteins present in highly diluted solutions, as well as easy immunological detection of separated substances. BJP was found in 24 out of 42 patients with CLL, 33 of 56 with NHL and 3 of 3 with Waldenström macroglobulinemia. Twenty-three patients were followed during the course of chemo- or radiotherapy. In 19 cases the BJP findings correlated well with clinical status. In no case of partial or complete clinical response did BJP completely disappear from the urine.

B-Lymphocytes↗
PubMed1989

Chromosomal characteristics of malignant lymphoma.

Results of a cytogenetic and morphological study of 60 malignant lymphomas (ML) are presented. The most often observed chromosome abnormalities were rearrangements involving 14q32, 11q13, 11q21-23, 6q15, 6q21, 12p11-12, 17p11-12, and extra chromosomes 18, 3, 21 and 7. Translocations involving 14q32, leading to the appearance of marker 14q+, were noted in 41% of the tumors. Strict correlations between karyotype and morphology of ML were not seen. However, rearrangements of 11q were mostly found in low-grade tumors and markers 6q- in high-grade tumors. The absence of t(14;18), which is regarded to be the most common abnormality in ML, and an unusually high incidence of t(11;14) in our series confirm the uneven geographical distribution of ML with these translocations. Chromosome abnormalities in ML and acute lymphoblastic leukemia are compared.

Adolescent↗
PubMed1989

[The clinical characteristics of hematosarcoma with primary skin involvement].

As many as 90 patients suffering from hematosarcomas associated with primary skin lesions were examined. This patients' group did not include patients with mycosis fungoides or with Sezary's syndrome. The clinical picture, ways and stages of the spreading of skin hematosarcomas were reviewed. Damage to the internal organs outstripped lymph nodes injuries in 1/3 of the patients. Half of the patients followed up until their death died at the height of acute leukemia. The survival appeared relatively high: the median period turned out to be 51 months, whereas 33% of the patients survived for 10 and more years. The survival was influenced by the sex and age of the patients as well as by the histological disease variant.

Adolescent↗
PubMed1988

[Leukemization of hematosarcomas with primary involvement of the skin].

Clinicomorphological investigation of 81 patients with different types of skin hematosarcomas was conducted. Stage IV of disease was diagnosed in 53 patients, leukemic involvement developed in 18 of them (34%). Leukemic bone involvement was shown to be the main cause of death in myelosarcomas and lymphoblastic lymphomas. There were no significant differences in the frequency of leukemic bone marrow involvement with relation to the site and nature of primary skin involvement. A clinical course of disease was determined by a skin tumor histological type. Some morphological features of bone marrow lymphoblasts in leukemic bone marrow involvement in skin hematosarcomas (irregular cell shape, a moderate nuclear-cytoplasmic ratio, azurophilic granulation, fine-grained patterns of PAS-positive substance) distinguished them from lymphoblasts in leukemic bone marrow involvement in hematosarcomas with a primary focus of another site.

Bone Marrow↗
PubMed1988

[Treatment and prognosis of recurrences of lymphosarcoma].

Short- and long-term results of various methods of chemotherapy of 547 adult lymphosarcoma patients with tumor recurrences were analyzed. Therapeutic tactics and prognosis were determined mainly by a morphological type of lymphosarcomas.

Adolescent↗
PubMed1988

[Immunoblastic lymphosarcoma in chronic lympholeukemia and prolymphocytic lymphosarcoma (Richter's syndrome)].

Available are three cases of Richter's syndrome, i.e. immunoblastic lymphosarcoma with plasmocytic differentiation which developed in patients with chronic lymphocytic leukemia and prolymphocytic (lymphocytic) lymphosarcoma. Clinical, anatomical and autopsy findings are analysed. The immunoblastic lymphosarcoma is suggested to arise either because of transformation of the tumor prolymphocytes (lymphocytes) due to the disease progression or can be promoted by a second tumor.

Female↗